Betamethasone + Neomycin

Generic Medicine Info
Indications and Dosage
Ocular inflammation with suspected or confirmed bacterial infection
Adult: As ophthalmic ointment containing betamethasone Na phosphate 0.1% w/w and neomycin sulfate 0.5% w/w: Apply ¼ inch long to the lower eye lid 2-3 times daily and/or at night. Usual treatment duration: Up to 7 days per course.

Corticosteroid-responsive dermatoses with secondary infection
Adult: As betamethasone (valerate) crm/oint containing 0.122% w/w and neomycin sulfate 0.5% w/w: Apply onto the affected area(s) 2-3 times daily.
Child: ≥2 yr: As cream/ointment containing betamethasone (as valerate) 0.122% w/w and neomycin sulfate 0.5% w/w: Apply onto the affected area(s) 2-3 times daily. Usual treatment duration: Up to 5 days/course.
Renal Impairment
Dose reduction may be necessary.
Hypersensitivity. Rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritus and primary cutaneous viral infections. Not to be used in otitis externa complicated by ear-drum perforation. Treatment of primary infected skin lesions caused by fungi or bacteria; primary or secondary infections due to yeast; or secondary infections due to Pseudomonas or Proteus species. Children <2 yr. Ophthalmic preparation: Not to be used in patients with glaucoma or herpetic keratitis.
Special Precautions
Avoid prolonged treatment as it may lead to systemic corticosteroid effects even withour occlusion. Avoid prolonged excessive application to the facial areas. Withdraw treatment if there is spread of the infection. Risk of glaucoma development if preparation enters eye(s). Regular monitoring is recommended when used in psoriasis due to treatment tolerance, rebound relapses, generalised pustular psoriasis or systemic toxicity. Increased risk of contact sensitisation when used for extended period or recurrently. Pregnancy and lactation. Ophthalmic preparation: Monitor intraocular pressure, cataract formation of unsuspected infections; evaluate treatment if there is no clinical improvement after 7 days. Not to be used for undiagnosed red eye.
Adverse Reactions
Prolonged use may cause local atrophic changes in the skin e.g. thining, striae and dilatation of superficial blood vessels. Local skin burning sensation, pruritus, pigmentation changes, allergic contact dermatitis and hypertrichosis. Ophthalmic preparation: Corneal ulceration, increased intraocular pressure, mydriasis, ptosis, epithelial punctate keratitis.
Acute overdosage is unlikely to occur. Prolonged excessive use may lead to sufficient systemic absorption resulting in symptoms of Cushing's syndrome, in which case, gradual withdrawal of the drug is recommended. Significant systemic absorption of neomycin sulfate may cause ototoxicity and nephrotoxicity. Treatment involves withdrawal of drug and monitoring general status, hearing acuity, renal and neuromuscular functions of the patient.
Drug Interactions
If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.
Description: Betamethasone valerate is a corticosteroid which is effective in inflammatory dermatoses. It is also effective in less responsive conditions such as psoriasis. Neomycin sulfate is a broad spectrum antibiotic. It is bactericidal against many bacteria which are commonly associated with skin infections.
Absorption: Betamethasone: Absorption through the skin depends on several factors e.g. presence of occlusive dressing, integrity of the epidermal barrier.
Distribution: Betamethasone: Bound to plasma proteins to varying extent.
Metabolism: Betamethasone: Largely metabolised hepatically.
Excretion: Betamethasone: Mainly excreted via the kidneys.
Store <25°C.
Disclaimer: This information is independently developed by MIMS based on Betamethasone + Neomycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Actnovate
  • Betacort-N
  • Beta-Dipo
  • Betama-EN
  • Beta-N
  • Betnovate-N
  • Clinivate-N Cream
  • Neobet
  • Patarvate-N
  • Tenovate-N
  • Topaben-N
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in